Results 151 to 160 of about 2,984 (199)

Letermovir for cytomegalovirus prophylaxis

, 2019
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Letermovir

Reactions Weekly
  +12 more sources

Letermovir

Reactions Weekly, 2023
  +5 more sources

Letermovir for the management of cytomegalovirus infection

Expert Opinion on Investigational Drugs, 2016
Cytomegalovirus (CMV) is a major cause of morbidity and mortality in immunocompromised patients. Available antivirals are fraught with adverse effects and risk for the development of CMV resistance. Letermovir is a novel antiviral in the late stages of drug development for the treatment and prevention of CMV. Areas covered: A MEDLINE search of the MeSH
Lyndsey J. Bowman, Jennifer Iuppa Melaragno, Daniel C. Brennan   +2 more
openaire   +2 more sources

Letermovir

Reactions Weekly, 2022
openaire   +2 more sources

Letermovir

Reactions Weekly, 2019
  +4 more sources

Letermovir: First Global Approval

Drugs, 2017
Letermovir (Prevymis™) is an orally or intravenously administered cytomegalovirus (CMV) DNA terminase complex inhibitor being developed by Merck & Co., Inc., under a global license from AiCuris Anti-infective Cures GmbH. Letermovir has been approved in Canada and the USA for the prophylaxis of CMV infection and disease in adult CMV-seropositive ...
openaire   +2 more sources

Letermovir

Reactions Weekly, 2021
openaire   +2 more sources

Drug interaction between letermovir and voriconazole after allogeneic hematopoietic cell transplantation

International Journal of Hematology, 2021
Toshihisa Nakashima, Yoshihiro Inamoto
exaly